Rallybio/$RLYB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Rallybio
Rallybio Corp is a clinical-stage biotechnology company engaged in the development of therapeutic candidates for severe and rare diseases. It focuses on the treatment of conditions related to complement dysregulation and hematologic disorders. The company's flagship program, RLYB116, is a C5 inhibitor being evaluated for potential use in diseases associated with complement dysregulation, including immune platelet transfusion refractoriness and refractory antiphospholipid syndrome. Its pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody candidate under investigation for the treatment of iron overload disorders.
Ticker
$RLYB
Sector
Primary listing
Employees
15
Headquarters
Website
Rallybio Metrics
BasicAdvanced
$27M
-
-$0.32
-1.05
-
Price and volume
Market cap
$27M
Beta
-1.05
52-week high
$0.95
52-week low
$0.22
Average daily volume
173K
Financial strength
Current ratio
14.744
Quick ratio
13.127
Long term debt to equity
0.171
Total debt to equity
0.314
Profitability
EBITDA (TTM)
-33.141
Gross margin (TTM)
-5,690.95%
Net profit margin (TTM)
-2,102.37%
Operating margin (TTM)
-4,934.72%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-28.35%
Return on equity (TTM)
-21.17%
Valuation
Price to revenue (TTM)
42.716
Price to book
0.43
Price to tangible book (TTM)
0.43
Price to free cash flow (TTM)
-0.823
Free cash flow yield (TTM)
-121.56%
Free cash flow per share (TTM)
-0.781
Growth
Revenue change (TTM)
12.71%
Earnings per share change (TTM)
-79.93%
3-year earnings per share growth (CAGR)
-46.52%
What the Analysts think about Rallybio
Analyst ratings (Buy, Hold, Sell) for Rallybio stock.
Rallybio Financial Performance
Revenues and expenses
Rallybio Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rallybio stock?
Rallybio (RLYB) has a market cap of $27M as of February 02, 2026.
What is the P/E ratio for Rallybio stock?
The price to earnings (P/E) ratio for Rallybio (RLYB) stock is 0 as of February 02, 2026.
Does Rallybio stock pay dividends?
No, Rallybio (RLYB) stock does not pay dividends to its shareholders as of February 02, 2026.
When is the next Rallybio dividend payment date?
Rallybio (RLYB) stock does not pay dividends to its shareholders.
What is the beta indicator for Rallybio?
Rallybio (RLYB) has a beta rating of -1.05. This means that it has an inverse relation to market volatility.